Driver mutation characteristics of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) in advanced non-small cell lung cancer-Reference-Cited by-同舟云学术

Driver mutation characteristics of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) in advanced non-small cell lung cancer

Published:2023-04 Issue: Volume:178 Page:229-236
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Daher Sameh,Zer Alona,Tschernichovsky Roi,Yacobi Rinat,Barshack Iris,Tsabari Shani,Rottenberg Yakir,Zick Aviad,Gottfried Teodor,Lobachov Anastasiya,Marom Edith M.,Urban Damien,Saad Akram,Gantz-Sorotsky Hadas,Onn Amir,Bar Jair

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference40 articles.

1. Impact of precision medicine in diverse cancers: A meta-analysis of phase II clinical trials;Schwaederle;J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.,2015

2. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N. Engl. J. Med.,2009

3. LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations;Yang;J. Clin. Oncol.,2012

4. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC;Ramalingam;N. Engl. J. Med.,2020

5. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer;Shaw;N. Engl. J. Med.,2020

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Elucidation of Therapeutic Mechanism of Lipopeptide Iturin A from Bacillus aryabhattai on Lung Cancer Through Integration of Network Pharmacology, Molecular Docking, Molecular Dynamics Simulation and In Vitro Analysis;2024-09-10

2. Signaling dynamics in coexisting monoclonal cell subpopulations unveil mechanisms of resistance to anti-cancer compounds;Cell Communication and Signaling;2024-07-26

3. Capivasertib reverses chemotherapy-induced esophageal cancer resistance via inhibiting Akt-associated Mcl-1 upregulation;Heliyon;2024-07

4. Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges;Frontiers in Immunology;2024-04-09

5. PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities;Pharmacological Research;2024-04